NCT04784767View on ClinicalTrials.gov

PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

April 5, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

October 30, 2023

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)

SpFN\_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial

DRUG

Sodium chloride, USP, for injection (0.9% NaCl)

Normal saline will be provided in a sterile, single-use 10 mL vial

BIOLOGICAL

50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)

SpFN\_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial

Trial Locations (1)

20910

WRAIR Clinical Trials Center, Silver Spring

All Listed Sponsors
collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

collaborator

Henry M. Jackson Foundation for the Advancement of Military Medicine

OTHER

lead

U.S. Army Medical Research and Development Command

FED

NCT04784767 - PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 | Biotech Hunter | Biotech Hunter